Replies to post #417736 on Amarin Corp Plc (AMRN)

[Whalatane]

Brave EPA

The overarching goal of this trial is to assess whether icosapent ethyl beneficially affects intermediate physiological measures associated with onset of AD in order to evaluate whether larger, multi-site, longer-duration Alzheimer's prevention trials are warranted to assess more definitive clinical outcomes.

IF Brave EPA is successful ...the FDA may fast track a trial ..say the size of MITIGATE ....but to suggest that it's possible to grant approval based on Brave- EPA alone is really stretching it IMHO
Kiwi